MX2009004081A - Metodo para restaurar el efecto de incretina. - Google Patents
Metodo para restaurar el efecto de incretina.Info
- Publication number
- MX2009004081A MX2009004081A MX2009004081A MX2009004081A MX2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A MX 2009004081 A MX2009004081 A MX 2009004081A
- Authority
- MX
- Mexico
- Prior art keywords
- restoring
- methods
- present
- insulin secretion
- incretin effect
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title abstract 2
- 239000000859 incretin Substances 0.000 title abstract 2
- 230000003914 insulin secretion Effects 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000000923 atherogenic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con métodos para tratar el síndrome metabólico, diabetes mellitus Tipo II, dislipidemia aterogénica y/u obesidad. La presente invención también se relaciona con métodos para restaurar el efecto de incretina, para restaurar el control fisiológico de niveles de glucagón, para restaurar la secreción de insulina de primera fase y restaurar la secreción de insulina dependiente de glucosa fisiológica. Los métodos de la presente invención comprenden la administración de un antagonista ic-receptor selectivo, tal como naltrindol guanidinilatado (GLTI), o derivados farmacéuticamente aceptados de los mismos a un sujeto con necesidad de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86222706P | 2006-10-20 | 2006-10-20 | |
| PCT/US2007/082084 WO2008051902A2 (en) | 2006-10-20 | 2007-10-22 | Method of restoring the incretin effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004081A true MX2009004081A (es) | 2009-06-18 |
Family
ID=39325299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004081A MX2009004081A (es) | 2006-10-20 | 2007-10-22 | Metodo para restaurar el efecto de incretina. |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US7893080B2 (es) |
| EP (2) | EP2724722B1 (es) |
| BR (1) | BRPI0718420A2 (es) |
| CA (1) | CA2666846C (es) |
| ES (1) | ES2618500T3 (es) |
| MX (1) | MX2009004081A (es) |
| PT (1) | PT2724722T (es) |
| SI (1) | SI2724722T1 (es) |
| WO (1) | WO2008051902A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009004081A (es) * | 2006-10-20 | 2009-06-18 | Cpd Llc | Metodo para restaurar el efecto de incretina. |
| MX2012006485A (es) * | 2009-12-07 | 2012-08-23 | Univ Georgia | Piridinon hidroxiclicopentil carboxamidas: inhibidores de la integrasa del vih con aplicaciones terapeuticas. |
| ES2787223T3 (es) | 2014-11-07 | 2020-10-15 | Univ Minnesota | Sales y composiciones útiles para tratar enfermedades |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272540A (en) | 1979-04-24 | 1981-06-09 | Sisa, Incorporated | 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them |
| IE51145B1 (en) | 1980-03-07 | 1986-10-15 | Efamol Ltd | Pharmaceutical and dietary compositions |
| US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
| HU201675B (en) | 1983-08-26 | 1990-12-28 | Ivan Balkanyi | Process for producing oral pharmaceutical compositions with unappetizing effect |
| US4478840A (en) | 1983-10-11 | 1984-10-23 | E. I. Du Pont De Nemours And Company | Appetite suppressing compositions and methods |
| US5208250A (en) | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US5428066A (en) | 1989-03-08 | 1995-06-27 | Larner; Joseph | Method of reducing elevated blood sugar in humans |
| US5843089A (en) | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
| US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
| US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| DE10075006I2 (de) * | 1991-06-21 | 2004-01-08 | Boehringer Ingelheim Pharma | Verwendung von (S)(+)-2-Äthoxy-4-[N-[1-(2-Piperidino-Phenyl)-3-Methyl-1-Butyl[Aminocarbonylmethyl]-Benzoesäure zur Herstellung eines Langzeitantidiabetikums. |
| US5866595A (en) * | 1991-09-26 | 1999-02-02 | The Regents Of The University Of California | Calcium antagonists for treatment of vascular restenosis |
| DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| US5772629A (en) | 1995-10-23 | 1998-06-30 | Localmed, Inc. | Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels |
| WO1997018781A1 (en) | 1995-11-20 | 1997-05-29 | University Of Miami | Method of treating nicotine dependence |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| GB9606076D0 (en) | 1996-03-22 | 1996-05-22 | Univ Birmingham | Diabetes treatment |
| WO1997036580A1 (en) * | 1996-03-29 | 1997-10-09 | 3-Dimensional Pharmaceuticals, Inc. | Amidinohydrazones as protease inhibitors |
| US6294559B1 (en) * | 1996-05-02 | 2001-09-25 | Merck & Co., Inc. | Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2 |
| US6387121B1 (en) | 1996-10-21 | 2002-05-14 | Inflow Dynamics Inc. | Vascular and endoluminal stents with improved coatings |
| US6026817A (en) | 1996-11-14 | 2000-02-22 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US5727570A (en) | 1996-11-14 | 1998-03-17 | Clemens; Anton H. | Method of treating hyperlipidemia in humans |
| US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US6103722A (en) | 1997-07-23 | 2000-08-15 | The Medical College Of Wisconsin Research Foundation Inc. | Ischemic preconditioning |
| US6242196B1 (en) | 1997-12-11 | 2001-06-05 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| CA2320900C (en) | 1998-03-19 | 2009-10-27 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| WO1999058120A1 (en) | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| US6280411B1 (en) * | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
| WO1999059997A1 (en) | 1998-05-18 | 1999-11-25 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| US6369039B1 (en) | 1998-06-30 | 2002-04-09 | Scimed Life Sytems, Inc. | High efficiency local drug delivery |
| US6500824B1 (en) | 1998-08-06 | 2002-12-31 | Regents Of The University Of Minnesota | Kappa (OP2) opioid receptor antagonists |
| WO2000024730A1 (en) | 1998-10-28 | 2000-05-04 | The University Of British Columbia | Organic vanadium(iii) complexes and their use |
| US6087385A (en) | 1998-10-30 | 2000-07-11 | University Of Mississippi | Flavonoid derivatives |
| US6419692B1 (en) * | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
| IL145712A0 (en) * | 1999-04-01 | 2002-07-25 | Esperion Therapeutics Inc | Ether compounds, compositions, and uses thereof |
| US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
| US6471979B2 (en) * | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6910310B2 (en) | 2002-09-03 | 2005-06-28 | Braided Accents Llc | Chair rail system and method |
| MX2009004081A (es) | 2006-10-20 | 2009-06-18 | Cpd Llc | Metodo para restaurar el efecto de incretina. |
-
2007
- 2007-10-22 MX MX2009004081A patent/MX2009004081A/es active IP Right Grant
- 2007-10-22 PT PT131975088T patent/PT2724722T/pt unknown
- 2007-10-22 BR BRPI0718420-4A2A patent/BRPI0718420A2/pt not_active Application Discontinuation
- 2007-10-22 EP EP13197508.8A patent/EP2724722B1/en not_active Not-in-force
- 2007-10-22 SI SI200731903A patent/SI2724722T1/sl unknown
- 2007-10-22 CA CA2666846A patent/CA2666846C/en not_active Expired - Fee Related
- 2007-10-22 ES ES13197508.8T patent/ES2618500T3/es active Active
- 2007-10-22 US US11/876,279 patent/US7893080B2/en not_active Expired - Fee Related
- 2007-10-22 EP EP07844505A patent/EP2083817A4/en not_active Withdrawn
- 2007-10-22 WO PCT/US2007/082084 patent/WO2008051902A2/en not_active Ceased
-
2010
- 2010-10-18 US US12/906,735 patent/US8445508B2/en not_active Expired - Fee Related
- 2010-10-18 US US12/906,740 patent/US8399474B2/en not_active Expired - Fee Related
-
2013
- 2013-02-22 US US13/774,388 patent/US8785469B2/en not_active Expired - Fee Related
- 2013-04-10 US US13/859,940 patent/US8829018B2/en not_active Expired - Fee Related
-
2014
- 2014-07-18 US US14/335,155 patent/US20140329844A1/en not_active Abandoned
- 2014-09-08 US US14/479,828 patent/US9987268B2/en not_active Expired - Fee Related
-
2018
- 2018-06-05 US US15/997,965 patent/US20190134023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150065535A1 (en) | 2015-03-05 |
| US20080108640A1 (en) | 2008-05-08 |
| US9987268B2 (en) | 2018-06-05 |
| US7893080B2 (en) | 2011-02-22 |
| EP2724722A1 (en) | 2014-04-30 |
| US20130172380A1 (en) | 2013-07-04 |
| US20110118293A1 (en) | 2011-05-19 |
| WO2008051902A3 (en) | 2008-07-10 |
| ES2618500T3 (es) | 2017-06-21 |
| CA2666846A1 (en) | 2008-05-02 |
| CA2666846C (en) | 2018-04-10 |
| US8829018B2 (en) | 2014-09-09 |
| EP2083817A4 (en) | 2009-12-23 |
| US20140329844A1 (en) | 2014-11-06 |
| US8399474B2 (en) | 2013-03-19 |
| US20110034501A1 (en) | 2011-02-10 |
| PT2724722T (pt) | 2017-03-14 |
| US8445508B2 (en) | 2013-05-21 |
| SI2724722T1 (sl) | 2017-07-31 |
| EP2083817A2 (en) | 2009-08-05 |
| US20190134023A1 (en) | 2019-05-09 |
| WO2008051902A2 (en) | 2008-05-02 |
| BRPI0718420A2 (pt) | 2013-11-12 |
| US20130224176A1 (en) | 2013-08-29 |
| US8785469B2 (en) | 2014-07-22 |
| EP2724722B1 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA89615C2 (ru) | Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
| WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2004056317A3 (en) | Compositions for the treatment and prevention of nephropathy | |
| WO2007124461A3 (en) | Glp-1 compounds | |
| WO2006086107A3 (en) | Methods and compositions for minimizing accrual of inhalable insulin in the lungs | |
| ZA200502247B (en) | Selected CGRP antagonists, method for production and use thereof as medicament. | |
| WO2007048026A3 (en) | Cgrp peptide antagonists and conjugates | |
| TNSN07080A1 (en) | Method of assembly of drug delivery devices | |
| WO2004000354A3 (en) | Method of treating the syndrome of lipodystrophy | |
| MXPA05006994A (es) | Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. | |
| WO2007111945A3 (en) | Method for management of diarrhea | |
| PL376450A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
| WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
| WO2006065722A3 (en) | Compositions and methods for pulmonary conditions | |
| Henry et al. | Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| MX2009004081A (es) | Metodo para restaurar el efecto de incretina. | |
| WO2005123109A3 (en) | Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use | |
| AU2012207301A8 (en) | Apolipoprotein AIV as an antidiabetic peptide | |
| IL182135A0 (en) | Liquid allergy vaccine formulation for ormucosal administration | |
| WO2006047392A3 (en) | Nicotinic-opioid synergy for analgesia | |
| WO2005067548A3 (en) | Use of ribose in recovery from anaesthesia | |
| WO2008046882A3 (en) | Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| GB | Transfer or rights | ||
| FG | Grant or registration |